<DOC>
	<DOCNO>NCT00838071</DOCNO>
	<brief_summary>The purpose study determine whether protective anti-HB serum level maintain 6 month uninterrupted treatment IGIV-HB Grifols , new specific hepatitis B immune globulin , patient previously undergone liver transplantation .</brief_summary>
	<brief_title>Evaluation Serum Levels Pharmacokinetics New Hepatitis B Immune Globulin Following Liver Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Hepatitis B Antibodies</mesh_term>
	<criteria>1 . Patients undergone liver transplantation due liver disease associate hepatitis B virus , least 1 year 5 year inclusion study . 2 . Patients required treatment HBIG , receive present . 3 . Patients 18 70 year age . 4 . The patient agree participate comply aspect protocol , include plan blood sample collection , sign informed consent form . 1 . Presence HBV DNA HBeAg indicate virus replication . 2 . Patients known allergy component HBIVIG , sorbitol ( e.g . patient present intolerance fructose ) . 3 . Patients know background severe frequent reaction product derive plasma . 4 . Patients present arterial hypertension clinically control . 5 . Patients present creatinine value &gt; 2 mg/dl , nephrotic syndrome renal failure . 6 . Patients present anaemia ( haemoglobin &lt; 11 g/dl ) . 7 . Patients treat interferon . 8 . The patient suffers acute chronic medical condition investigator believe may interfere development interpretation study . 9 . The patient know abuse alcohol , opiates , psychotropic agent drug chemical substance ; do past 12 month . 10 . Pregnant woman time inclusion may pregnant next 7 month breastfeed woman . 11 . Patients participate another clinical study , receive another investigational product last 3 month . 12 . Possibility patient may treat product contain immunoglobulin period 7 month . 13 . Suspicion condition may affect patient 's compliance , include expect survival less 1 year . 14 . Any patient frozen serum sample previous first study medication infusion . 15 . Patients selective IgA deficiency .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Hepatitis B</keyword>
	<keyword>HBV</keyword>
	<keyword>Anti-hepatitis B antibody</keyword>
	<keyword>Immunoglobulins</keyword>
	<keyword>liver transplantation</keyword>
	<keyword>Protective level</keyword>
	<keyword>Recurrence</keyword>
	<keyword>Intravenous</keyword>
</DOC>